Pacira Pharmaceuticals, Inc.

Embodiments of the present disclosure are related to multivesicular liposome formulations encapsulating zinc meloxicam complex microparticles. Methods of making the zinc meloxicam complex microparticles and administering the zinc meloxicam complex microparticles encapsulated in multivesicular liposome formulations and their use as medicaments are also provided.

Embodiments of the present disclosure relates to commercial manufacturing process of making bupivacaine multivesicular liposomes with improved yield and desired particle size distribution.

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Embodiments of the present disclosure relate to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Embodiments of the present disclosure relate to the use of bupivacaine multivesicular liposomes (MVLs) as stellate ganglion block (SGB) for treating or ameliorating various diseases and conditions, including but not limited to cardiac electrical storm or cardiac arrythmia/dysrhythmia following heart surgery.

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Embodiments of the present disclosure relate to methods of using bupivacaine multivesicular liposomes (MVLs) as stellate ganglion block (SGB) for treating or ameliorating a sympathetic nervous system disorder associated with overactive or unbalanced sympathetic nervous system, including but not limited to, Raynaud's syndrome, post-mastectomy pain, reflex sympathetic dystrophy (RSD), phantom limb pain, hyperhidrosis, trigeminal neuralgia/facial pain, scleroderma, and long COVID.

Embodiments of the present application relate to compositions bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process with large particle diameter span.

Embodiments of the present application relate to batches of bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process using independently operating dual tangential flow filtration modules.